Method for selecting patients responsive for cancer treatments

The present invention is directed to a method of quantifying intracellular metabolite effluxes in permeabilized cancer cells for selecting cancer patients responsive for a cancer treatment, the method comprising the steps of: a) providing a sample of cancer cells taken from a patient; b) permeabilizing said cancer cells; c) incubating said permeabilized cancer cells in a reaction medium for a period of time allowing biological activity of intracellular organelles and accumulation of metabolites produced by said activity into the reaction medium in the presence of a substrate or substrates relating to a metabolite efflux or effluxes of interest, wherein said substrates used are at least glutamine and pyruvate; d) determining the quantity of metabolites relating to said metabolite efflux or effluxes of interest accumulated in the reaction medium during step c); and e) comparing the amounts of metabolites determined in step d) to equal measurements performed on control samples of the same tissue type and assessing the aggressiveness of the cancer cells or the treatment response of the cancer cells to a drug affecting a metabolic pathway or pathways relating to said metabolite efflux or effluxes of interest. 1. A method of quantifying intracellular metabolite effluxes in permeabilized cancer cells for selecting cancer patients responsive for a cancer treatment , the method comprising the steps of:a) providing a sample of cancer cells taken from a patient;b) permeabilizing said cancer cells;c) incubating said permeabilized cancer cells in a reaction medium for a period of time allowing biological activity of intracellular organelles and accumulation of metabolites produced by said activity into the reaction medium in the presence of a substrate or substrates relating to a metabolite efflux or effluxes of interest, wherein the substrates used are at least glutamine and pyruvate;d) determining the quantity of metabolites relating to said metabolite efflux or effluxes of ...

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS IIIA or MPS IIIB disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS IIIA or MPS IIIB disorder relative to individuals without the MPS IIIA or MPS IIIB disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; andwherein the biomarker is selected from a group consisting of{'sub': '3', 'Formula III: [GlcNS-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula IV: [GlcNS-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula V: [GlcNAc-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula VI: [GlcNAc-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula VIII: [GlcN-GlcA-GlcN(Ac)0-1](SOR)0-4;'}{'sub': '3', 'Formula IX: [GlcNAc6S-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula X: [GlcNAc6S-GlcA-GlcN(Ac)0-1](SOR)0-2;'}GlcN-IdoA-GlcNAc;GlcN-IdoA2S-GlcNAc;GlcN-IdoA-GlcNS;GlcN-IdoA-GlcNAc6S;GlcN-IdoA2-GlcNAc6S; andGlcN-IdoA-GlcNS6S.32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)-1](SOR); or ...

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Blood lactate range targets and nutritional formulations and protocols to support patients

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130.-. (canceled)31. A method for determining in an individual , the presence , identity , and/or severity of MPS I disorder , the method comprising:a) generating a biomarker comprising of one or more non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of glycosaminoglycans, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS I disorder relative to individuals without the MPS I disorder; andb) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence and/or the measure of the amount of the biomarker are utilized to determine the presence, identity, and/or severity of MPS I disorder; andwherein the biomarker is selected from a group consisting ofFormula I-A: IdoA-GlcNAc;Formula I-B: IdoA-GlcNS;Formula I-C: IdoA-GlcNS6S;{'sub': 3', 'n, 'Formula XII: [IdoA-GalNAc](SOR), wherein n is 0-2;'}{'sub': 3', 'n, 'Formula XXI: [IdoA-GlcN(Ac)m-IdoA](SOR), where m is 0-1 and n is 0-4;'}{'sub': 3', 'n, 'Formula XXII: [IdoA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3; and'}{'sub': 3', 'n, 'Formula XXIII: [GlcA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3.'}32. The method of claim 31 , wherein the biomarker is selected from the group consisting of: Formula I-A: IdoA-GlcNAc; Formula I-B: IdoA-GlcNS; Formula I-C: IdoA-GlcNS6S; and Formula XII: [IdoA-GalNAc](SO3R)n claim 31 , wherein n is 0-2.33. The method of claim 31 , wherein the biomarker is selected from the ...

IN VITRO METHOD FOR THE EARLY DETECTION OF A POTENTIAL INFLAMMATION, IN PARTICULAR ASSOCIATED WITH REJECTION OF A TRANSPLANT, A NEURODEGENERATIVE DISORDER OR A DEPRESSION

An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems. 112-. (canceled)13. An in vitro method for the early detection of a potential inflammation caused by a rejection of a transplant , comprising quantitatively determining the level of kynurenine in saliva.14. The method of wherein the potential inflammation is caused by the rejection of a transplant organ selected from the group comprising liver claim 13 , pancreas claim 13 , heart claim 13 , lung and kidney.15. The method of wherein the potential inflammation is caused by a transplant selected from the group comprising cornea-transplants claim 13 , retina-transplants claim 13 , cartilage-transplants and skin-transplants.16. The method of wherein the potential inflammation is caused by the rejection of an artificial transplant.17. The method of wherein the artificial transplant is selected from the group comprising bone replacements claim 16 , joint replacements claim 16 , tooth implants claim 16 , cartilage implants claim 16 , breast implants and penis implants.18. An in vitro method for monitoring the recovery of a patient after having received a transplant comprising quantitatively determining the level of kynurenine in saliva.19. An in vitro method for controlling therapy in a patient after having received a transplant comprising quantitatively determining the level of kynurenine in saliva.20. An in vitro method for detecting and/or monitoring a neurodegenerative disorder claim 16 , comprising determininghe level of kynurenine in saliva.21. The method of wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease claim 20 , vascular dementia claim 20 , Parkinson's disease claim 20 , postoperative cognitive dysfunction claim 20 , and depression.22. The ...

Continuous monitoring of blood lactate and ongoing targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Means and Methods for Diagnosing Pancreatic Cancer in a Subject Based on a Biomarker Panel

The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising the steps of: (a) determining in at least one sample of said subject the amounts of a group of diagnostic biomarkers comprising (i) at least one diagnostic amino acid, said diagnostic amino acid being proline, histidine or tryptophan, preferably, being proline; (ii) at least one diagnostic ceramide, said diagnostic ceramide being ceramide (d18:1,C24:0) or ceramide (d18:2,C24:0), preferably being ceramide (d18:1,C24:0); (iii) at least one diagnostic sphingomyelin, said diagnostic sphingomyelin being sphingomyelin (35:1), sphingomyelin (d17:1,C16:0), sphingomyelin (41:2) or sphingomyelin (d18:2,C17:0), preferably being sphingomyelin (35:1); and (iv) CA19-9; and (b) comparing said amounts of the diagnostic biomarkers with a reference, whereby pancreatic cancer is diagnosed. Moreover, the present invention relates to a method for determining the probability for a subject to suffer from pancreatic cancer, and to devices and uses related to said methods.

APPARATUS FOR ANALYSIS OF EGGS

The present invention relates to a process for the non-destructive determination of gender, developmental stage and/or viability of an avian embryo in an egg, comprising (a) detecting at least a first developmental marker compound selected from sugars and/or amino acids, precursors and metabolites thereof in an egg at a time period of from the beginning of the incubation of the egg until the hatching; (b) measuring the amount of the at least first detected developmental marker compound, and (c) comparing the amount to a base line established for male and female, developmental stage of the embryo, and/or alive and deceased or non-developed embryo, to determine whether the embryo is viable, male and/or female, and/or the developmental stage of the embryo. 134.-. (canceled)35. An apparatus or system comprising(a) a quantitative analytic apparatus selected from the group consisting of a magnetic resonance spectrometer, a spectral resonance spectrometer, a GC coupled with a suitable detector, an HPLC coupled with a suitable detector, a fluorescence spectrometer and an enzyme-linked immunosorbent assay system for measuring the level of at least a first developmental marker compound selected from sugars and/or amino acids, precursors and metabolites thereof in an egg;(b) a microprocessor configured to perform multivariate statistical analysis of the level of the at least a first developmental marker to compare the amount to a base line established for male and female, developmental stage of the embryo, and/or alive and deceased or non-developed embryo, to determine whether the embryo is viable, male and/or female, and/or the developmental stage of the embryo and identify viable female and viable male eggs; and(c) an incubator for subjecting the viable female and/or viable male eggs to an incubation and hatching process to form a predominantly female or male chick population, and/or for subjecting the viable egg selections to an incubation and hatching process in line with ...

MICROSAMPLING DETECTION IN DIABETES

The present disclosure relates to methods of detecting various analytes, including glycated hemoglobin (HbA1c) and total hemoglobin (THb), in a biological sample obtained with a microsampling device. 11. A method of determining a fraction of glycated hemoglobin (HbAc) in a sample , comprising:(a) eluting a biological sample from a microsampling device used to collect the biological sample an individual;(b) extracting hemoglobin from the biological sample;{'b': '1', '(c) measuring the concentration of HbAc and the concentration of total hemoglobin (THb);'}{'b': '1', '(d) calculating the fraction of HbAc in the THb.'}2. The method of claim 1 , wherein the biological sample is obtained from an individual having or suspected of having diabetes.3. The method of claim 1 , wherein the biological sample is a dried fluid.4. The method of claim 1 , wherein the biological sample is dried serum claim 1 , dried capillary blood claim 1 , or dried whole blood.5. The method of claim 1 , wherein the biological sample was collected from a patient via fingerstick.6. The method of claim 1 , wherein the biological sample is eluted from an absorbent tip of the microsampling device by incubating the absorbent tip in water.7. The method of claim 1 , wherein extraction comprises contacting the biological sample with a lysis buffer to lyse erythrocytes in the sample.8. The method of further comprising contacting the sample with sodium nitrite.9. The method of further comprising contacting the sample with one or more of a protease claim 7 , sodium azide claim 7 , and fructosyl peptideoxidase.10. The method of claim 1 , wherein the concentration of THb is determined by measuring absorbance.111. The method of claim 1 , wherein the concentration of HbAc is determined by measuring an indirect marker.12. The method of claim 11 , wherein the indirect marker is hydrogen peroxide.131. The method of claim 1 , wherein the THb or the HbAc are measured by mass spectroscopy.141. The method of claim 1 , ...

DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER

Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD. 1. A method for improving behavioral performance in a subject , the method comprising: "wherein the blood level of the metabolite in the subject is altered relative to the blood level of the metabolite observed in a subject not suffering from or showing symptoms of anxiety, Fragile X, Rett syndrome, obsessive compulsive disorder, attention deficit disorder, autistic disorder (classic autism), Asperger's disorder (Asperger syndrome), pervasive developmental, disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder (CDD), or autism spectrum disorder (ASD); and", 'measuring the blood level of a metabolite in the subject, wherein the metabolite is selected from the group consisting of: 4-ethylphenylsulfate, indolepyruvate, glycolate, imidazole pyruvate, and N-acetylserine,'}{'i': 'Bacteroides', 'administering a composition comprising bacteria to the subject until an improvement in the behavioral performance in the subject is observed.'}2. The method of claim 1 , wherein the subject suffers from anxiety claim 1 , ASD claim 1 , Fragile X claim 1 , Rett syndrome claim 1 , obsessive compulsive disorder claim 1 , attention deficit disorder claim 1 , autistic disorder claim 1 , Asperger's disorder claim 1 , PDD-NOS claim 1 , or CDD3. The method of claim 2 , wherein the subject suffers from ASD.4. (canceled)5. The method of claim 1 , wherein administering the composition comprises fecal transplantation.6. (canceled)7BacteroidesB. fragilis, B. thetaiotaomicron, B. vulgatus. The method of claim 1 , wherein the bacteria is claim 1 , or a mixture thereof.8. The method of claim 1 , wherein the composition is a probiotic composition claim 1 , a nutraceutical claim 1 , a pharmaceutical composition claim 1 , or a mixture thereof.9. The method of ...

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS III disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS III disorder relative to individuals without the MPS III disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; and{'sub': m', 'n', '3', 'p, 'wherein the biomarker is of Formula II: [GlcN(Ac)-(IdoA/GlcA)-GlcN(Ac)](SOR), wherein (IdoA/GlcA) is IdoA or GlcA; m and n are each independently 0 or 1; p is 0, 1, 2, 3, 4, or 5; and R is hydrogen or a negative charge.'}32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)](SOR) claim 31 , wherein n is 0-1 and p is 0 claim 31 , 1 claim 31 , 2 claim 31 , or 3; or Formula VI: [GlcNAc-GlcA-GlcN(Ac)](SOR) claim 31 , wherein n is 0-1 and p is 0 claim 31 , 1 claim 31 , or 2.33. The method of claim 32 , wherein the biomarker of Formula V is selected from a group consisting of GlcNAc-IdoA-GlcNAc claim 32 , GlcNAc-IdoA2S-GlcNAc claim 32 , GlcNAc-IdoA-GlcNS claim 32 , GlcNAc-IdoA2S-GlcNS ...

METHOD OF EXTRACTING ORGAN METABOLIC FUNCTIONS USING ORAL GLUCOSE TOLERANCE TESTS AND DEVICE THEREFOR

A method of extracting organ metabolic functions using oral glucose tolerance tests (OGTTs) comprises: a step of measuring an amount of change over time in plasma glucose and plasma insulin at a regular time interval after a subject has consumed a certain quantity of a glucose solution; a step of extracting parameters associated with organ metabolism in a human body by applying the amount of change over time of the measured glucose and insulin to a human organ function model; and a step of diagnosing the metabolic function state of the subject using the extracted parameters. 1. A method of extracting organ metabolic functions using oral glucose tolerance tests (OGTTs) comprising:ingesting a dose of glucose solution to a subject and measuring an amount of change over time in plasma glucose and plasma insulin at a regular time interval;extracting parameters related to organ metabolism in a human body by applying the change over time in plasma glucose and plasma insulin to a human organ function model; anddiagnosing metabolic function state of the subject using extracted parameters.2. The method of extracting organ metabolic functions using oral glucose tolerance tests (OGTTs) according to claim 1 , wherein the human organ function model comprises a glucose compartment and an insulin compartment claim 1 , wherein the glucose compartment comprises a glucose compartment in a liver and a blood glucose compartment in a plasma claim 1 , and the insulin compartment comprises compartments of plasma insulin claim 1 , liver insulin claim 1 , peripheral insulin claim 1 , liver receptor and peripheral receptor.3. The method of extracting organ metabolic functions using oral glucose tolerance tests (OGTTs) according to claim 2 , wherein the extracted parameters comprise at least one among gut glucose absorption rate claim 2 , insulin reduction rate claim 2 , number of receptors in liver claim 2 , number of receptors in peripheral tissues claim 2 , glucose sensitivity for insulin ...

In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression

타액 중의 키누레닌 수준을 측정하는, 잠재적 염증, 특히 이식 거부반응의 조기 검출을 위한 시험관 내 방법이 개시된다. 상기 시험 방법은 쉽게 수행될 수 있으며 및 잠재적 문제의 조기 검출을 허용한다.

Gender, viability and / or developmental stage determination of avian embryos in egg

FIELD: agriculture.SUBSTANCE: invention relates to agriculture, namely a method for controlling the incubation of an avian embryo in an egg to obtain a sample of eggs by determining the gender, developmental stage and / or viability of an avian embryo. In order to determine the gender of an avian embryo, the level of glucose, choline and / or valine is measured in the period from the start of incubation of the egg to hatching, followed by comparing this number with the base value set for the male and female embryo. To determine the developmental stage or viability of the avian embryo in the egg, the level of trimethylglycine, aspartate, arginine, glutamate, glutamine or proline is measured in the period from the start of incubation of the egg to hatching, and then this amount is compared to the base value set for the developmental stage of the embryo, either alive or dead, or an undeveloped embryo to determine if the embryo is viable or the stage of development of the embryo.EFFECT: invention provides for the determination of the viability of avian embryos, the control of their development, and the separation of male and female eggs for further use.27 cl, 2 dwg, 2 tbl, 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 681 536 C2 (51) МПК G01N 33/50 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК G01N 33/487 (2018.08); A01K 45/00 (2018.08) (21)(22) Заявка: 2015106609, 30.07.2013 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): ИН ОВО Би.Ви. (NL) Дата регистрации: 07.03.2019 30.07.2012 NL 2009256; 30.07.2012 US 61/677,227; 30.07.2012 NL 2009255 (43) Дата публикации заявки: 20.09.2016 Бюл. № 26 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 02.03.2015 C 2 C 2 (45) Опубликовано: 07.03.2019 Бюл. № 7 102210708 A, 10.12.2011. CA 2750877 A1, 08.07.2010. JP 20100264785, 29.01.2010. WO 02083848 A2, 24.10.2002. RU 2161403 C1, 10.01.2001. RU 2403711 С2, 14.04.2008. SU 1671680 A1, ...

In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression

An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems.

Gender, viability and/or developmental stage determination of avian embryos in ovo

The present invention relates to a process for the non-destructive determination of gender, developmental stage and/or viability of an avian embryo in an egg, comprising (a) detecting at least a first developmental marker compound selected from sugars and/or amino acids, precursors and metabolites thereof in an egg at a time period of from the beginning of the incubation of the egg until the hatching;(b) measuring the amount of the at least first detected developmental marker compound,and(c) comparing the amount to a base line established for male and female, developmental stage of the embryo, and/or alive and deceased or non-developed embryo, to determine whether the embryo is viable, male and/or female, and/or the developmental stage of the embryo.

In vitro early detection method for potential inflammation particularly associated with transplant rejection, neurodegenerative disease or depression

In vitro method for the early detection of possible inflammation associated with transplant rejection

Un método in vitro para la detección temprana de una posible inflamación causada por un rechazo de un trasplante, en donde el nivel de quinurenina en la saliva se determina cuantitativamente y en donde el valor de la quinurenina medido en el paciente a diagnosticar se compara con el valor promedio obtenido de una cohorte de personas comparable que no padecen esta enfermedad, por lo el valor de la quinurenina en pacientes que muestran signos tempranos de inflamación está aumentado. An in vitro method for the early detection of possible inflammation caused by transplant rejection, where the level of kinurenine in saliva is quantitatively determined and where the value of kinurenine measured in the patient to be diagnosed is compared with the average value obtained from a comparable cohort of people who do not suffer from this disease, therefore the value of kynurenine in patients showing early signs of inflammation is increased.

Gender, viability and/or developmental stage determination of avian embryos in ovo.

La presente invención se refiere a un proceso para la determinación no destructiva de género, de etapa de desarrollo y/o viabilidad de un embrión aviar en un huevo, que comprende (a) detectar por lo menos un primer compuesto marcador de desarrollo seleccionado de azúcares y/o aminoácidos, precursores y metabolitos de los mismos en un huevo en un período de tiempo desde el inicio de la incubación del huevo hasta la eclosión; (b) medir la cantidad de por lo menos un primer compuesto o marcador de desarrollo detectado, y (c) comparar la cantidad a una línea base establecida para macho y hembra, etapa de desarrollo del embrión, y/o embrión vivo y fallecido o no desarrollado, para determinar si el embrión es viable, macho y/o hembra, y/o la etapa de desarrollo del embrión.

DETERMINATION OF SEX, ABILITY AND / OR DEVELOPMENT STEPS FOR PENCIL EMBRYOES IN OVO

Detection of oligosaccharides

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Means and methods for diagnosing pancreatic cancer in a subject based on a biomarker panel

The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising the steps of: (a) determining in at least one sample of said subject the amounts of a group of diagnostic biomarkers comprising (i) at least one diagnostic amino acid, said diagnostic amino acid being proline, histidine or tryptophan, preferably, being proline; (ii) at least one diagnostic ceramide, said diagnostic ceramide being ceramide (d18:1,C24:0) or ceramide (d18:2,C24:0), preferably being ceramide (d18:1,C24:0); (iii) at least one diagnostic sphingomyelin, said diagnostic sphingomyelin being sphingomyelin (35:1), sphingomyelin (d17:1,C16:0), sphingomyelin (41 :2) or sphingomyelin (d18:2,C17:0), preferably being sphingomyelin (35:1); and (iv) CA19-9; and (b) comparing said amounts of the diagnostic biomarkers with a reference, whereby pancreatic cancer is diagnosed. Moreover, the present invention relates to a method for determining the probability for a subject to suffer from pancreatic cancer, and to devices and uses related to said methods.

METHOD FOR DIAGNOSIS OF DISORDER MPS IIIB

Παρεχόμενες στο παρόν είναι μέθοδοι για ανίχνευση ολιγοσακχαριδίων σε ένα βιολογικό δείγμα. Σε ειδικές περιπτώσεις, το βιολογικό δείγμα παρέχεται από ένα άτομο που υποφέρει από μία διαταραχή που συνδυάζεται με μη κανονική συσσώρευση γλυκοζαμινογλυκάνης.

Gender, viability and/or developmental stage determination of avian embryos in ovo

Винахід стосується способу відбору групи яєць однієї статі, стадії розвитку та/або життєздатності шляхом неруйнуючого визначення статі, стадії розвитку та/або життєздатності пташиного ембріона в кожному яйці, який включає: (a) визначення щонайменше першого маркера розвитку, вибраного з триметилгліцину, аспартату, арганіну, глутамату, глутаміну й проліну та/або першого маркера статі вибраного з глюкози, холіну та/або валіну в алантоїсній рідині у яйці протягом часу від початку інкубування яйця до його вилуплення; (b) вимірювання кількості щонайменше першого маркера розвитку та/або першого маркера статі, та (c) порівняння цієї кількості з базовим значенням для чоловічого та жіночого ембріона, стадії розвитку ембріона та/або живого, мертвого або нерозвиненого ембріона для того, щоб визначити, чи є даний ембріон життєздатним, чоловічим або жіночим і на якій стадії розвитку він знаходиться.

Detection of oligosaccharides

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Phenylalanine dehydrogenase mutant with improved substrate specificity and application thereof

本发明公开了一种底物特异性提高的苯丙氨酸脱氢酶突变体及其应用，属于酶工程和微生物工程技术领域。本发明的苯丙氨酸脱氢酶突变体对苯丙酮酸的底物特异性较野生型有了明显的改善，同时，对L‑正缬氨酸、L‑亮氨酸、L‑缬氨酸、L‑苯甘氨酸的特异性较野生型有了明显的降低，因此，将本发明的苯丙氨酸脱氢酶突变体用于血液等样品中苯丙氨酸含量的检测时，可排除其他氨基酸的干扰，提高检测灵敏度，在制备苯丙氨酸检测试剂盒以及苯丙酮尿症检测试剂盒方面具有极高的应用前景。

Diagnosis and treatment of autism spectrum disorders

本申请涉及孤独症谱系障碍的诊断和治疗。本文公开了用于诊断和治疗罹患焦虑、孤独症谱系障碍(ASD)、或具有ASD的一种或更多种症状的病理状况的受试者的组合物、系统、和方法。

Gender, viability and/or developmental stage determination of avian embryos in ovo

The present invention relates to a process for the non-destructive determination of gender, developmental stage and/or viability of an avian embryo in an egg, comprising (a) detecting at least a first developmental marker compound selected from sugars and/or amino acids, precursors and metabolites thereof in an egg at a time period of from the beginning of the incubation of the egg until the hatching;(b) measuring the amount of the at least first detected developmental marker compound,and(c) comparing the amount to a base line established for male and female, developmental stage of the embryo, and/or alive and deceased or non-developed embryo, to determine whether the embryo is viable, male and/or female, and/or the developmental stage of the embryo.

Method for simultaneous diagnosis of hereditary diseases

FIELD: medicine. SUBSTANCE: method for simultaneous diagnosis of hereditary diseases based on the use of a biochip with oligonucleotide targets immobilized on its surface is proposed, including detection of point mutations in CUL7, NBAS, DIA1, FAH and GJB2 genes, causing 3M syndrome, SOPH syndrome, hereditary enzyme type 1 methemoglobinemia, type 1 tyrosinemia and type 1A hereditary nonsyndromic deafness, respectively. EFFECT: invention allows to diagnose hereditary diseases in the shortest possible time. 2 dwg, 5 tbl

insulin resistance model

본원은 생물학적 세포에서 인슐린 반응을 정량화하는 데 사용하기 위한 인슐린 저항성 리포터를 개시한다. 이들 생물학적 세포는 인슐린 저항성 리포터를 포함하는 줄기 세포 조성물 또는 이의 유도체일 수 있다. 줄기 세포 유도체는 췌장, 뇌, 지방, 근육 또는 간 세포와 같은 인슐린 반응성 세포, 조직 또는 오가노이드, 또는 이들의 조직 또는 오가노이드를 포함하나, 이에 제한되지 않는다. 또한 본원은 인슐린 저항성을 검사하기 위한 모델로서 상기 인슐린 저항성 리포터 및 이러한 인슐린 저항성 리포터를 갖는 세포를 사용하고 잠재적으로 인슐린 저항성과 연관된 질환 또는 장애의 치료에 유용한 화합물을 스크리닝하는 방법을 개시한다. 인슐린 저항성 리포터를 포함하는 세포는 예를 들어, 비-알콜성 지방간 질환 또는 지방간염의 결과로서 간 인슐린 저항성을 조사하는데 사용될 수 있는 간 세포 또는 간 오가노이드 조성물일 수 있다.

Method for the simultaneous diagnosis of hereditary diseases

Method for diagnosing mps iiib disorder

Method for early diagnostics of cervical intraepithelial neoplasias (cin) based on metabolic markers study

FIELD: medicine. SUBSTANCE: invention is intended for early diagnostics of cervical intraepithelial neoplasias (CIN). Cervix pathology is identified. The level of predictor markers expression is determined by means of a Western blot analysis with chemiluminescence detection and real-time PCR. At expression levels of HIF1alpha 0.029, GLUT1 782.9±156.5, IGFBP-3 0.038±0.0076, HK2 36.4, VDAC1 70, CIN1 (LSIL) is diagnosed. At expression levels of HIF1alpha 0.03, GLUT1 1154.2±88.7, IGFBP-3 0.02±0.005, HK2 44.9, VDAC1 87, CIN2-3 (HSIL) is diagnosed. EFFECT: effective diagnosis of cervical intraepithelial neoplasias at earlier stages. 5 dwg, 1 tbl, 3 ex

In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression

An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems.

Point-of-care device for the colorimetric determination of L-phenylalanine in biological samples

Methods and devices for testing and monitoring L-phenylalanine in biological samples are provided.

Method for measuring and targeting an oxidative phosphorylation metabolism

The invention relates to the implementation of a low-temperature cell test and to a method for determining whether a cell uses for its energy production the oxidative phosphorylation (OxPhos) or glycolysis, wherein the low-temperature sensitivity is indicative of the OxPhos metabolism.

Processo para determinação não destruidora do gênero e/ou etapa de desenvolvimento de um embrião de ave em um ovo

determinação do gênero, viabilidade e/ ou etapa de desenvolvimento de embriões de aves in ovo. a presente invenção se relaciona com um processo para a determinação não destruidora do gênero, etapa de desenvolvimento e/ ou viabilidade de um embrião de ave em um ovo, compreendendo (a) deteção pelo menos de um primeiro composto marcador do desenvolvimento selecionado de açúcares e/ ou aminoácidos, seus precursores e metabolitos em um ovo a um período de tempo do início da incubação do ovo até à eclosão; (b) medição da quantidade do pelo menos primeiro composto marcador do desenvolvimento detetado, e (c) comparação da quantidade com uma linha de base estabelecida para machos e fêmeas, etapa de desenvolvimento do embrião, e/ ou embrião vivo e doente ou não desenvolvido, para se determinar se o embrião é viável, macho e/ ou fêmea, e/ ou a etapa de desenvolvimento do embrião.

Assessment of disease risk factors in correlation with neu5gc ingested in food

Compositions and methods for treating dysregulated wound healing

The present disclosure relates to compositions and methods for treating a dysregulated wound healing, for improving wound healing, for inhibiting scar formation, for treating a subject with Ehlers Danlos syndrome (EDS), and for treating a subject diagnosed with a heart attack. The present disclosure further relates to compositions and methods for predicting future cardiac risk in a subject who has suffered a heart attack, and predicting risk of future cardiac disease in a subject suffering a heart attack.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Continuous monitoring of blood lactate and ongoing targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Compositions and methods for treating dysregulated wound healing

The present disclosure relates to compositions and methods for treating a dysregulated wound healing, for improving wound healing, for inhibiting scar formation, for treating a subject with Ehlers Danlos syndrome (EDS), and for treating a subject diagnosed with a heart attack. The present disclosure further relates to compositions and methods for predicting future cardiac risk in a subject who has suffered a heart attack, and predicting risk of future cardiac disease in a subject suffering a heart attack.

Microsampling detection in diabetes

The present disclosure relates to methods of detecting various analytes, including glycated hemoglobin (HbA1c) and total hemoglobin (THb), in a biological sample obtained with a microsampling device.

Non-invasive functional companion assays for oncogene targeted therapy for brain cancer

The present disclosure relates to methods for determining the metabolic responder status of a subject having glioblastoma (GBM) and adjusting the course of treatment accordingly. The disclosure further relates to methods of treating GBM and other EGFR-mediated cancers. The disclosure further relates to methods of identifying effective treatments for subjects having GBM.

Metabolic biomarkers for assessing heart failure in a single ventricle pediatric subject

Methods to assess a pediatric subject having a single ventricle heart include identifying a difference between concentration levels of metabolic biomarkers and reference concentration levels and then assessing the pediatric subject based on the identified differences.

Kit for early diagnosis and monitoring of tumors

The present invention relates to a ready-to-use kit for the early diagnosis of tumors by the analysis of a sample of a biological liquid and its use for the early diagnosis of tumors.

Systems and methods for monitoring of blood lactate and targeting of blood lactate via nutritional support

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Multiplexing homocysteine and cysteine in first-tier screening assays

A method of multiplexing Hcy and/or Cys in a first-tier screening assay includes: contacting a blood sample with a reducing agent optionally in the presence of a solvent to convert at least one of a Hcy dimer, a Hcy-protein complex, a Cys dimer different from the homocysteine dimer, or a Cys-protein complex in the blood sample to a Hcy and/or Cys monomer thereby forming a monomer sample; reacting the Hcy and/or Cys monomer in the monomer sample with a thiol derivatizing agent to form a thiol derivatized sample comprising a thiol derivatized Hcy and/or Cys monomer; and optionally converting a carboxylic acid or a carboxylate group in the thiol derivatized Hcy and/or Cys monomer to an ester, forming a thiol-and-ester derivatized sample comprising a thiol-and-ester derivatized Hcy and/or Cys monomer. The method can be used to determine a level of tHcy, a level of tCys, and/or a level of CysT in a blood sample, and screen for CBS deficiency, HCU, or hyperhomocysteinemia.

Integrated drug discovery platform for inborn error of metabolism disorders

The invention relates to in vivo systems and high throughput screening platform for drugs applicable in inborn error of metabolism (IEM) disorders. More specifically, the invention provides yeast screening system of candidate therapeutic compounds applicable in IEM disorders associated with accumulation of at least one metabolite. The systems of the invention comprise yeast cell/s that carry at least one manipulation in at least one yeast metabolic pathway, that leads to accumulation of said metabolite.

腎病變小分子生物標記及其應用

本發明涉及生物標記、方法，以及分析套組，係用於鑑定及篩選腎病變並且監控腎病變的治療。

Methods for analyzing glycan-derived monosaccharides

The present disclosure provides a method for analyzing glycan-derived monosaccharides in a sample. The present disclosure also provides a method for detecting or monitoring a disease or disorder in a patient. In addition, the present disclosure provides a method of determining aberrant glycotransferase activity. The present disclosure further provides a system for analyzing or comparing glycates in a sample.

In vitro method for the early detection of a neurodegenerative disorder or a depression using kynurenine as a marker

Integrated drug discovery platform for inborn error of metabolism disorders

Integrated drug discovery platform for inborn error of metabolism disorders

The invention relates to in vivo systems and high throughput screening platform for drugs applicable in inborn error of metabolism (IEM) disorders. More specifically, the invention provides yeast screening system of candidate therapeutic compounds applicable in IEM disorders associated with accumulation of at least one metabolite. The systems of the invention comprise yeast cell/s that carry at least one manipulation in at least one yeast metabolic pathway, that leads to accumulation of said metabolite.

Integrated drug discovery platform for inborn error of metabolism disorders

The invention relates to in vivo systems and high throughput screening platform for drugs applicable in inborn error of metabolism (IBM) disorders. More specifically, the invention provides yeast screening system of candidate therapeutic compounds applicable in IBM disorders associated with accumulation of at least one metabolite. The systems of the invention comprise yeast cell/s that carry at least one manipulation in at least one yeast metabolic pathway, that leads to accumulation of said metabolite.

一种alg1-cdg、pmm2-cdg生物标记物的合成方法及其应用

本发明公开了一种ALG1‑CDG、PMM2‑CDG生物标记物的合成方法及其应用，本发明涉及ALG1‑CDG、PMM2‑CDG生物标记物(唾液酸‑半乳糖‑两个N‑乙酰氨基葡萄糖：Sia‑Gal‑Gn2)体外化学酶合成方法以及将其连接到载体蛋白上提高其免疫原性的制备方法。本发明进一步涉及所述抗体在对ALG1‑CDG、PMM2‑CDG两种先天性糖激化缺陷(CDG)临床检测中的用途，与传统基因组学测序、糖组学分析以及高通量筛选等临床检测方法相比，通过抗体与血清中生物标记物的特异性结合可以更快，更便捷，更节约的做出诊断。

Determination of tryptophan metabolites for assessing liver cell function

The present invention relates to a method for assessing damage in cells expressing the tryptophan degradation pathway, comprising (a) determining the amount of tryptophan and / or the amount of at least one tryptophan degradation product in a sample comprising metabolites of said cells expressing the tryptophan degradation pathway, (b) comparing the amount determined in step (a) with a reference amount, (c) thereby determining damage in cells expressing the tryptophan degradation pathway. The present invention further relates to a method for identifying a compound detrimental to cells expressing the tryptophan degradation pathway, and to the use of the amount of tryptophan and / or the amount of at least one tryptophan degradation product in a sample from cells expressing the tryptophan degradation pathway for determining damage in cells expressing the tryptophan degradation pathway and / or for identifying a compound detrimental to cells expressing the tryptophan degradation pathway. The invention also related to a device for assessing damage in cells expressing the tryptophan degradation pathway, to a kit comprising instructions to carry out the method of the present invention, to a method for assessing liver damage and / or impairment of liver function in a subject, and to a method for assessing if treatment of liver damage and / or impairment of liver function is effective in a subject.

一种alg1-cdg、pmm2-cdg生物标记物的合成方法及其应用

本发明公开了一种ALG1‑CDG、PMM2‑CDG生物标记物的合成方法及其应用，本发明涉及ALG1‑CDG、PMM2‑CDG生物标记物(唾液酸‑半乳糖‑两个N‑乙酰氨基葡萄糖：Sia‑Gal‑Gn2)体外化学酶合成方法以及将其连接到载体蛋白上提高其免疫原性的制备方法。本发明进一步涉及所述抗体在对ALG1‑CDG、PMM2‑CDG两种先天性糖激化缺陷(CDG)临床检测中的用途，与传统基因组学测序、糖组学分析以及高通量筛选等临床检测方法相比，通过抗体与血清中生物标记物的特异性结合可以更快，更便捷，更节约的做出诊断。

胰岛素抵抗模型

本文公开了用于量化生物细胞中胰岛素反应性的胰岛素抵抗报告物。这些生物细胞可以是包括胰岛素抵抗报告物的干细胞组合物或其衍生物。干细胞衍生物包括但不限于胰岛素反应性细胞、组织或类器官，例如胰腺、脑、脂肪、肌肉或肝细胞，或其组织或类组织。本文还公开了使用所述胰岛素抵抗报告物和具有这些胰岛素抵抗报告物的细胞作为模型来检查胰岛素抵抗的方法，以及筛选可能用于治疗与胰岛素抵抗相关的疾病或病症的化合物。包括胰岛素抵抗报告物的细胞可以是肝细胞或肝脏类器官组合物，其可以用于研究例如由于非酒精性脂肪性肝病或脂肪性肝炎引起的肝胰岛素抵抗。

孤独症谱系障碍的诊断和治疗

本申请涉及孤独症谱系障碍的诊断和治疗。本文公开了用于诊断和治疗罹患焦虑、孤独症谱系障碍(ASD)、或具有ASD的一种或更多种症状的病理状况的受试者的组合物、系统、和方法。

Model for insulin resistance

一种alg1-cdg、pmm2-cdg生物标记物的合成方法及其应用

本发明公开了一种ALG1‑CDG、PMM2‑CDG生物标记物的合成方法及其应用，本发明涉及ALG1‑CDG、PMM2‑CDG生物标记物(唾液酸‑半乳糖‑两个N‑乙酰氨基葡萄糖：Sia‑Gal‑Gn2)体外化学酶合成方法以及将其连接到载体蛋白上提高其免疫原性的制备方法。本发明进一步涉及所述抗体在对ALG1‑CDG、PMM2‑CDG两种先天性糖激化缺陷(CDG)临床检测中的用途，与传统基因组学测序、糖组学分析以及高通量筛选等临床检测方法相比，通过抗体与血清中生物标记物的特异性结合可以更快，更便捷，更节约的做出诊断。

糖尿病的微量取样检测

本公开文本涉及对用微量取样装置获得的生物样品中包括糖化血红蛋白(HbA1c)和总血红蛋白(THb)在内的各种分析物进行检测的方法。

一种底物特异性提高的苯丙氨酸脱氢酶突变体及其应用

本发明公开了一种底物特异性提高的苯丙氨酸脱氢酶突变体及其应用，属于酶工程和微生物工程技术领域。本发明的苯丙氨酸脱氢酶突变体对苯丙酮酸的底物特异性较野生型有了明显的改善，同时，对L‑正缬氨酸、L‑亮氨酸、L‑缬氨酸、L‑苯甘氨酸的特异性较野生型有了明显的降低，因此，将本发明的苯丙氨酸脱氢酶突变体用于血液等样品中苯丙氨酸含量的检测时，可排除其他氨基酸的干扰，提高检测灵敏度，在制备苯丙氨酸检测试剂盒以及苯丙酮尿症检测试剂盒方面具有极高的应用前景。

Non-invasive functional companion assays for oncogene targeted therapy for brain cancer

一种检测糖代谢异常的方法及其预防及治疗

本发明是有关于一种检测糖类代谢异常的方法，包括检测检体中GPx2基因表达、GPx2蛋白表达量、或GPx2的蛋白活性，并与一正常个体的GPx2表达量进行比较，其中该个体的GPx2表达量显著低于该正常个体的GPx2表达量代表该个体具有糖类代谢异常的状态。本发明另提供一种GPx2用于制备治疗预防第二型糖尿病的医药组合物的用途。

In vitro method for the early detection of a potential inflammation, in particular associated with rejection of a transplant, a neurodegenerative disorder or a depression

An in vitro method for the early detection of a potential inflammation, in particular a rejection of a transplant is disclosed, wherein the level of kynurenine in saliva is determined. The test method can be easily performed and allows the early detection of potential problems.

Detection of oligosaccharides

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Blood lactate range targets and nutritional formulations and protocols to support patients

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.